<DOC>
	<DOCNO>NCT02644538</DOCNO>
	<brief_summary>This study evaluate whether PegIFN alfa-2a add improve CHB patient HBsAg clearance end 48 week treatment . The CHB patient receive nucleot ( ) ides anti-virus treatment reach HBV DNA &lt; 1000 copies/ml HBsAg &lt; 3000 IU/ml , randomly assign two group : One group continue nucleot ( ) ides treatment 72 week , add PegIFN alfa-2a basis original treatment 48 week , follow 24 week .</brief_summary>
	<brief_title>Addition PegIFN Alfa-2a CHB Patients Treated With Nucleot ( ) Ides</brief_title>
	<detailed_description>nucleot ( ) ides potent inhibitor hepatitis B viral ( HBV ) replication , long-term therapy may require , difficult CHB patient achieve HBsAg clearance use nucleot ( ) ides . Therefore , need take long-term therapy chronic hepatitis B ( CHB ) choose use nucleot ( ) ides , another way , nucleot ( ) ides resistance important clinical risk . More young patient want stop treating , discontinuation nucleot ( ) ides feasible strategy reduce resistance . However , really easy relapse patient arrive HBsAg clearance . PegIFN alfa-2a clear HBV direct anti-viral immune regulation mechanism include enhance natural killer cell response , increase cluster differentiation 8 ( CD8 + ) T lymphocytes mechanism restore enhance immune response patient CHB ; 's , patient safety discontinuing .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female subjects,1865 year 2. positive hepatitis B surface antigen ( HBsAg ) negative antibody HBsAg ( antiHBs antibody ) least 6 month NAs treat 3. nucleot ( ) ides monotherapy ( include lamivudine , adefovir , entecavir , tenofovir ) achieve HBV DNA &lt; 1000 copies/mL HBsAg &lt; 3000 IU/mL , positive negative HBeAg , negative antiHBs antibody 4 . Subjects contraindication Peginterferon alfa therapy detail label ( Hypersensitivity active substance , alpha interferon , excipients ; Autoimmune hepatitis ; Severe hepatic dysfunction decompensated cirrhosis liver ; A history severe preexist cardiac disease , include unstable uncontrolled cardiac disease previous six month ) 5 . Subjects coinfected Hepatitis A Virus , Hepatitis C Virus HIV 6 . Female subject pregnant breast feed Peginterferon alfa treatment commence , aware requirement use effective method contraception therapy 7 . Written inform consent sign . 1. positive Hepatitis A Virus Ab , HCVRNA positive Hepatitis C Virus Ab , HDV Ab , HEV Ab positive HIV Ab screen period 2 . Hepatocellular carcinoma ( HCC ) alpha feto protein ( AFP ) level 100 ng/ml Hepatic malignant potential Imaging examination AFP level 100 ng/ml 3 month 3 . Compensated Decompensated liver cirrhosis : history cirrhosis nucleot ( ) ides treatment ChildPugh score â‰¥ 5 Complications liver cirrhosis ascites , hepatic encephalopathy , esophageal gastric varix bleed 4 . Autoimmune disease include Autoimmune hepatitis Psoriasis 5 . Pregnant woman lactate woman patient pregnancy plan willing use contraception study period 6 . A history immunoregulation drug therapy within one year entry include IFN 7 . Have history alcohol abuse 8 . With severe psychiatric condition nervous disease epilepsy , depression , mania , epilepsy , schizophrenia 9 . A neutrophil count less 1500 per cubic millimeter platelet count le 90,000 per cubic millimeter 10 . Severe organ dysfunction 11 . With malignant tumor ( exclude cure one ) 12 . Uncontrolled diabetes , hypertension thyroid disease 13 . A serum creatinine level 1.5 time upper limit normal range 14 . Hypersensitivity interferon ( IFN ) active substance , ineligible IFN 15 . Participate clinical study time 16 . Patients unsuitable research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HBsAg clearance</keyword>
</DOC>